CORCEPT THERAPEUTICS INC (CORT) Free cash flow
- Free cash flow · 12 months (USD): Value $106.92M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value 12.87%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $106.92M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $109.70M − $2.78M ≈ $106.92M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | 12.87% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $106.92M ÷ $830.81M × 100 ≈ 12.87% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $109.70M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 1.99× | Operating cash flow / net income. Period ending 2026-06-30. $109.70M ÷ $55.18M ≈ 1.99× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 109.70M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | 2.78M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | 106.92M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 830.81M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | 55.18M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $106.92M | (m) | $109.70M | $2.78M | (m) | $830.81M | (m) | $55.18M | (m) | (m) | 12.87% | 1.99× |
| 2026-03-31 | $120.15M | (m) | $120.45M | $308.00K | (m) | $769.10M | (m) | $47.34M | (m) | (m) | 15.62% | 2.54× |
| 2025-12-31 | $141.78M | (m) | $142.00M | $211.00K | (m) | $761.41M | (m) | $99.65M | (m) | (m) | 18.62% | 1.42× |
| 2025-09-30 | $163.10M | (m) | $163.38M | $282.00K | (m) | $741.17M | (m) | $106.11M | (m) | (m) | 22.01% | 1.54× |
| 2025-06-30 | $180.27M | (m) | $182.19M | $1.92M | (m) | $716.08M | (m) | $133.66M | (m) | (m) | 25.17% | 1.36× |
| 2025-03-31 | $177.16M | (m) | $179.44M | $2.28M | (m) | $685.45M | (m) | $133.99M | (m) | (m) | 25.85% | 1.34× |
| 2024-12-31 | $195.90M | (m) | $198.07M | $2.17M | (m) | $675.04M | (m) | $141.21M | (m) | (m) | 29.02% | 1.40× |
| 2024-09-30 | $142.60M | (m) | $144.65M | $2.05M | (m) | $628.55M | (m) | $141.82M | (m) | (m) | 22.69% | 1.02× |
| 2024-06-30 | $123.28M | (m) | $123.73M | $453.00K | (m) | $569.61M | (m) | $125.98M | (m) | (m) | 21.64% | 0.98× |
| 2024-03-31 | (m) | (m) | $124.84M | (m) | (m) | $523.53M | (m) | $118.02M | (m) | (m) | (m) | 1.06× |
| 2023-12-31 | $126.90M | (m) | $127.04M | $139.00K | (m) | $482.38M | (m) | $106.14M | (m) | (m) | 26.31% | 1.20× |
| 2023-09-30 | $154.37M | (m) | $154.54M | $170.00K | (m) | $450.03M | (m) | $91.39M | (m) | (m) | 34.30% | 1.69× |
| 2023-06-30 | $134.79M | (m) | $135.28M | $484.00K | (m) | $428.15M | (m) | $94.62M | (m) | (m) | 31.48% | 1.43× |
| 2023-03-31 | $110.63M | (m) | $111.03M | $401.00K | (m) | $413.82M | (m) | $94.50M | (m) | (m) | 26.73% | 1.17× |
| 2022-12-31 | $119.91M | (m) | $120.32M | $413.00K | (m) | $401.86M | (m) | $101.42M | (m) | (m) | 29.84% | 1.19× |
| 2022-09-30 | $135.91M | (m) | $136.36M | $447.00K | (m) | $397.62M | (m) | $116.87M | (m) | (m) | 34.18% | 1.17× |
| 2022-06-30 | $151.16M | (m) | $151.42M | $255.00K | (m) | $392.03M | (m) | $112.73M | (m) | (m) | 38.56% | 1.34× |
| 2022-03-31 | $177.36M | (m) | $177.72M | $355.00K | (m) | $380.23M | (m) | $111.84M | (m) | (m) | 46.65% | 1.59× |
| 2021-12-31 | $167.42M | (m) | $167.89M | $469.00K | (m) | $365.98M | (m) | $112.51M | (m) | (m) | 45.75% | 1.49× |
| 2021-09-30 | $152.70M | (m) | $153.54M | $835.00K | (m) | $352.89M | (m) | $106.45M | (m) | (m) | 43.27% | 1.44× |
| 2021-06-30 | $133.88M | (m) | $135.28M | $1.39M | (m) | $343.09M | (m) | $97.61M | (m) | (m) | 39.02% | 1.39× |
| 2021-03-31 | $142.80M | (m) | $144.12M | $1.32M | (m) | $340.06M | (m) | $99.41M | (m) | (m) | 41.99% | 1.45× |
| 2020-12-31 | $150.73M | (m) | $151.97M | $1.24M | (m) | $353.87M | (m) | $106.01M | (m) | (m) | 42.59% | 1.43× |
| 2020-09-30 | $164.41M | (m) | $165.35M | $942.00K | (m) | $356.03M | (m) | $109.40M | (m) | (m) | 46.18% | 1.51× |
| 2020-06-30 | $172.83M | (m) | $173.34M | $510.00K | (m) | $351.21M | (m) | $114.11M | (m) | (m) | 49.21% | 1.52× |
| 2020-03-31 | $144.83M | (m) | $145.71M | $873.00K | (m) | $334.90M | (m) | $105.97M | (m) | (m) | 43.25% | 1.37× |
| 2019-12-31 | $135.03M | (m) | $136.12M | $1.09M | (m) | $306.49M | (m) | $94.18M | (m) | (m) | 44.06% | 1.45× |
| 2019-09-30 | $108.12M | (m) | $109.18M | $1.07M | (m) | $285.42M | (m) | $86.81M | (m) | (m) | 37.88% | 1.26× |
| 2019-06-30 | $114.44M | (m) | $115.26M | $825.00K | (m) | $268.36M | (m) | $78.22M | (m) | (m) | 42.64% | 1.47× |
| 2019-03-31 | $104.44M | (m) | $104.92M | $478.00K | (m) | $258.42M | (m) | $76.22M | (m) | (m) | 40.41% | 1.38× |
| 2018-12-31 | $115.37M | (m) | $115.67M | $298.00K | (m) | $251.25M | (m) | $75.41M | (m) | (m) | 45.92% | 1.53× |
| 2018-09-30 | $118.81M | (m) | $119.03M | $214.00K | (m) | (m) | (m) | $151.73M | (m) | (m) | (m) | 0.78× |
| 2018-06-30 | $85.20M | (m) | $85.45M | $251.00K | (m) | (m) | (m) | $147.74M | (m) | (m) | (m) | 0.58× |
| 2018-03-31 | $85.42M | (m) | $85.80M | $386.00K | (m) | (m) | (m) | $142.19M | (m) | (m) | (m) | 0.60× |
| 2017-12-31 | $60.52M | (m) | $60.94M | $419.00K | (m) | (m) | (m) | $129.12M | (m) | (m) | (m) | 0.47× |
| 2017-09-30 | $40.16M | (m) | $40.62M | $465.00K | (m) | (m) | (m) | $35.39M | (m) | (m) | (m) | 1.15× |
| 2017-06-30 | $38.16M | (m) | $38.63M | $473.00K | (m) | (m) | (m) | $24.22M | (m) | (m) | (m) | 1.60× |
| 2017-03-31 | $24.37M | (m) | $24.66M | $282.00K | (m) | (m) | (m) | $12.55M | (m) | (m) | (m) | 1.97× |
| 2016-12-31 | $18.20M | (m) | $18.39M | $194.00K | (m) | (m) | (m) | $8.14M | (m) | (m) | (m) | 2.26× |
| 2016-09-30 | $17.88M | (m) | $17.98M | $102.00K | (m) | (m) | (m) | $4.50M | (m) | (m) | (m) | 3.99× |
| 2016-06-30 | $9.92M | (m) | $9.93M | $12.00K | (m) | (m) | (m) | $1.32M | (m) | (m) | (m) | 7.55× |
| 2016-03-31 | $8.20M | (m) | $8.20M | $5.00K | (m) | (m) | (m) | $-1.60M | (m) | (m) | (m) | -5.14× |
| 2015-12-31 | $3.11M | (m) | $3.13M | $17.00K | (m) | (m) | (m) | $-6.41M | (m) | (m) | (m) | -0.49× |
| 2015-09-30 | $-2.47M | (m) | $-2.44M | $34.00K | (m) | (m) | (m) | $-11.26M | (m) | (m) | (m) | 0.22× |
| 2015-06-30 | $-9.30M | (m) | $-9.25M | $50.00K | (m) | (m) | (m) | $-16.67M | (m) | (m) | (m) | 0.55× |
| 2015-03-31 | $-18.19M | (m) | $-18.09M | $98.00K | (m) | (m) | (m) | $-22.28M | (m) | (m) | (m) | 0.81× |
| 2014-12-31 | $-27.55M | (m) | $-27.38M | $174.00K | (m) | (m) | (m) | $-31.38M | (m) | (m) | (m) | 0.87× |
| 2014-09-30 | $-33.85M | (m) | $-33.64M | $214.00K | (m) | (m) | (m) | $-38.61M | (m) | (m) | (m) | 0.87× |
| 2014-06-30 | $-36.58M | (m) | $-36.31M | $263.00K | (m) | (m) | (m) | $-43.51M | (m) | (m) | (m) | 0.83× |
| 2014-03-31 | $-36.78M | (m) | $-36.56M | $219.00K | (m) | (m) | (m) | $-47.86M | (m) | (m) | (m) | 0.76× |
| 2013-12-31 | $-37.19M | (m) | $-37.06M | $127.00K | (m) | (m) | (m) | $-46.01M | (m) | (m) | (m) | 0.81× |
| 2013-09-30 | $-38.28M | (m) | $-38.13M | $145.00K | (m) | (m) | (m) | $-46.01M | (m) | (m) | (m) | 0.83× |
| 2013-06-30 | $-38.89M | (m) | $-38.76M | $132.00K | (m) | (m) | (m) | $-43.40M | (m) | (m) | (m) | 0.89× |
| 2013-03-31 | $-37.58M | (m) | $-37.42M | $162.00K | (m) | (m) | (m) | $-39.10M | (m) | (m) | (m) | 0.96× |
| 2012-12-31 | $-36.17M | (m) | $-36.02M | $151.00K | (m) | (m) | (m) | $-38.05M | (m) | (m) | (m) | 0.95× |
| 2012-09-30 | (m) | (m) | $-33.57M | (m) | (m) | (m) | (m) | $-36.86M | (m) | (m) | (m) | 0.91× |
| 2012-06-30 | (m) | (m) | $-30.95M | (m) | (m) | (m) | (m) | $-35.00M | (m) | (m) | (m) | 0.88× |
| 2012-03-31 | (m) | (m) | $-30.26M | (m) | (m) | (m) | (m) | $-36.29M | (m) | (m) | (m) | 0.83× |
| 2011-12-31 | $-27.43M | (m) | $-27.40M | $25.00K | (m) | (m) | (m) | $-32.35M | (m) | (m) | (m) | 0.85× |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $-22.29M | (m) | (m) | (m) | (m) | $-25.97M | (m) | (m) | (m) | 0.86× |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $-17.97M | (m) | (m) | $29.00K | (m) | $-20.17M | (m) | (m) | (m) | 0.89× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |